加载中
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
前收盘价
US$2.94
−US$0.57 · -16.24%
盘后
US$2.99
+US$0.05 · +1.70%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
日内区间
当前US$2.94
52周区间
当前US$2.94
盘中时间采用ET。市场数据可能有所延迟。
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
日内区间
当前US$2.94
52周区间
当前US$2.94
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 11.93万 USD | — | — | — | 11.88万 USD |
| 毛利 | −11.93万 USD | — | — | — | −11.88万 USD |
| 研究与开发 | 366.87万 USD | 288.2万 USD | 479.45万 USD | 1333.53万 USD | 1794.71万 USD |
| 销售、一般及管理费用 | 424.28万 USD | 413.28万 USD | 442.82万 USD | 503.55万 USD | 573.43万 USD |
| 营业费用 | 779.23万 USD | 701.47万 USD | 922.28万 USD | 1837.08万 USD | 2368.13万 USD |
| 利息收入 | 2558 USD | 15.35万 USD | 28.98万 USD | 6.35万 USD | 1.12万 USD |
| 折旧和摊销 | 11.93万 USD | 18.6万 USD | 18.35万 USD | 11.82万 USD | 11.88万 USD |
| 营业利润 | −791.16万 USD | −701.47万 USD | −922.28万 USD | −1837.08万 USD | −2368.13万 USD |
| 净利润 | −718.55万 USD | −617万 USD | −837.44万 USD | −1754.89万 USD | −1334.32万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
